Why the study?
As SGLT2 inhibitors are foundational heart failure therapy, clinicians need familiarity to implement their use and limit potential adverse effects.
Design
Review and practical guide
Authors
Loading...
Supports SGLT2 inhibitor use as foundational HF therapy; leaves open implementation questions in routine practice.
This review provides an updated evidence-based practical guide for prescribing SGLT2 inhibitors as foundational therapy in patients with heart failure.
Monzo et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: